

Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2

Scientific brief
8 February 2021



Introduction

Increasing numbers of pregnant women with COVID-19 are being reported globally (1), and the potential for mother-to-child transmission (vertical transmission) of SARS-CoV-2, either *in utero*, intrapartum or in the early postnatal period is of concern. In general, respiratory viruses, like SARS-CoV-2, are not easily transmitted *in utero*, with no evidence for *in utero* transmission of other respiratory coronavirus infections (SARS-CoV or MERS-CoV) and only few case reports for other respiratory pathogens like influenza (2).

While most neonates born to infected women test negative for SARS-CoV-2, one review found that 1.9% (95/4907) of neonates tested positive at age 24 hours or less (3)¹. Neonates present largely with symptoms which are not severe (4, 5). At present, the extent to which SARS-CoV-2 vertical transmission occurs, and timing of such transmission, is unclear. Indeed, determining infection of the neonate, and when it occurs, has been challenging. Although two categorization systems have been proposed (6, 7), there is a lack of standardized international consensus definitions. Such consensus definitions are key to enable comparison of data across studies, and to determine potential interventions to improve clinical outcomes.

Methods

This scientific brief was prepared based on results of evidence synthesis and a WHO expert consultation. The WHO COVID-19 LENS (Living Evidence Synthesis) working group consolidated available evidence, based on rapid reviews of the literature and results of a living systematic review on pregnancy and COVID-19 (up to October 7, 2020)(3), on potential mechanisms of vertical transmission of infectious pathogens, feasibility of vertical transmission of SARS-CoV-2, data related to interpretation of positive SARS-CoV-2 virologic and serologic neonatal tests, lessons from diagnosis of other congenital infections, and existing proposed definitions to classify timing of vertical transmission of SARS-CoV-2 (6, 7). WHO convened a multidisciplinary, international panel of experts between October and November 2020 to review the evidence and propose a consensus initial classification system for the timing of vertical transmission of SARS-CoV-2 (Annex 1). The panel included experts in obstetrics, neonatology, paediatrics, epidemiology, virology, infectious disease, congenital infections, and placental pathology. The selection of the panel ensured geographic representation, gender balance, and no important conflicts of interest, in accordance with WHO standard procedures.

Review of the evidence

Mechanisms of vertical transmission of infectious pathogens

In utero transmission can occur through the haematogenous route, or more rarely the ascending route (2). Most pathogens transmitted *in utero* are those in which systemic (bloodstream) infection occurs in a pregnant woman to permit the

¹ Results up to November 29, 2020. Regular updates of the results of this living systematic review before peer-review will be published on a dedicated website (<https://www.birmingham.ac.uk/research/whocollaborating-centre/pregcov/index.aspx>)

pathogen to access the placenta. Once the pathogen reaches the placenta, it must cross the maternal-placental interface (either through infection of placental cells or through disruption of the placental barrier) to obtain access to fetal vessels, reach the fetus and cause infection (8). The risk of fetal infection may increase or decrease over the course of pregnancy depending on the pathogen (9).

Intrapartum transmission occurs during labour and childbirth, and requires exposure of the neonate to the infectious pathogen in maternal blood, vaginal secretions, or faeces during the birth process, and for the pathogen to be able to reach an appropriate host cell to result in infection of the neonate (10).

Postnatal transmission can occur through breastfeeding, and requires infant exposure to breast milk containing an infectious pathogen, the pathogen to reach target sites in the infant through the oral/gastrointestinal route, and for the pathogen to overcome infant defence systems (11). Postnatal transmission may also occur from an infected mother to her infant through respiratory or other infectious maternal secretions, or through contact with other infected caregivers or fomites (12).

Feasibility of vertical transmission of SARS-CoV-2

In utero transmission: From a pathophysiologic viewpoint, *in utero* SARS-CoV-2 transmission is possible. Viraemia due to SARS-CoV-2 although infrequent (10%; 95% CI 5-18%, 200/1512 blood samples), appears to be more likely to occur in those with severe disease (13). In addition, the cell-membrane associated angiotensin-converting enzyme 2 (ACE-2) receptor and transmembrane protease serine 2 (TMPRSS2) required for SARS-CoV-2 cellular entry have been identified in placental cells, although there are conflicting data related to the extent of co-expression and whether there is differential expression by gestational age (14, 15). Finally, SARS-CoV-2 can be associated with vascular damage, including hypercoagulopathy in pregnant women. In a systematic review, histopathologic placenta findings of fetal and/or maternal vascular malperfusion were seen in 35.3% (95% CI 27.7–43.0%, 53/150 cases) and 46% (95% CI 38.1–53.9%, 69/150 cases) of placentas examined, respectively (16). With ischaemic injury to the placenta, SARS-CoV-2 could reach the fetus without requiring placental cell infection. ACE-2 and TMPRSS2 can be found in the human fetal lung as well as other fetal tissues (17, 18). Thus, should virus reach the fetus, fetal infection is possible.

Intrapartum transmission: SARS-CoV-2 appears to rarely be detected in vaginal swabs in pregnant women (5 cases reported) (3)¹. However, SARS-CoV-2 RNA shedding is frequent (43% (934/2149)) in the faeces of infected individuals (19). Faecal contamination of the vaginal canal/vulva during labour and childbirth could potentially allow SARS-CoV-2 viral contamination of the neonatal oro/nasopharynx during vaginal birth (20). There may also be viral contamination in the environment during labour and childbirth or immediately after birth, due to droplets and aerosols generated by infected women during active labour, as well as maternal faecal contamination of the nearby environment, particularly during vaginal birth, which can lead to viral infection by the neonate immediately following birth (21). This may make it difficult to distinguish infant viral infection during passage through the birth canal from horizontal viral infection of SARS-CoV-2 in the immediate postnatal period.

Postnatal transmission: Postnatal transmission of SARS-CoV-2 appears to account for the majority of infections reported in neonates, likely representing exposure to the infected mother, other caregivers or fomites (3, 4). While SARS-CoV-2 has been detected by reverse transcription polymerase chain reaction (RT-PCR)-based assays in breast milk, it appears to be uncommon and to date no replication-competent virus has been detected (22). SARS-CoV-2-specific IgG, IgM and IgA have been detected in breast milk (11, 23); it is unknown if these antibodies would be protective against infection in a breastfed infant. In the postnatal period, infants may be exposed to SARS-CoV-2 from an infected mother, other caregivers and/or the neonate's environment, making the source of postnatal infection, should it occur, difficult to determine.

¹ Results up to November 29, 2020. Regular updates of the results of this living systematic review before peer-review will be published on a dedicated website (<https://www.birmingham.ac.uk/research/whocollaborating-centre/pregcov/index.aspx>)

System for classifying timing of SARS-CoV-2 vertical transmission

The evaluation of the frequency and timing of vertical transmission of SARS-CoV-2 raises some methodological challenges. The virus is primarily transmitted through the respiratory route and respiratory samples are primarily used for diagnosis, making it difficult to differentiate *in utero* or intrapartum transmission from postnatal transmission. Based on a review of other congenital infections (9, 24) and what is known about modes of transmission and diagnosis of SARS-CoV-2, a number of issues were considered during the development of the classification system, as described below.

1. *Definition and timing of maternal infection:* Maternal infection is defined as per WHO COVID-19 case definitions (25). There are only limited data on fetal outcomes of women who had SARS-CoV-2 in early pregnancy. There are some case reports of first or early second trimester pregnancy loss in women with symptomatic COVID-19, but several of these cases lack data on SARS-CoV-2 detection in the corresponding placenta and/or fetus (26, 27). The rate of spontaneous abortion (<13 weeks gestation) in women with SARS-CoV-2 infection in the first trimester does not appear to be increased when compared to women with ongoing pregnancies (11% (11/100) vs 9.3% (12/125)) (28). The few reports of amniocentesis in women with recent/recovered SARS-CoV-2 infection have not shown evidence of amniotic fluid infection (29, 30). However, because the potential for *in utero* transmission with maternal infection in early pregnancy is unknown, for the diagnosis of *in utero* infection, documented SARS-CoV-2 maternal infection at any time during pregnancy is considered appropriate; for diagnosis of intrapartum and postnatal transmission, maternal infection must be diagnosed near the time of childbirth (from 14 days prior to 2 days after birth. See Annex 1).
2. *Virologic testing:* The SARS-CoV-2 RT-PCR assay detects the presence of virus genetic fragments and does not assess whether there is replicating virus. Thus, a single positive RT-PCR in a respiratory sample in a neonate may indicate either active viral replication; viral fragments acquired during passage through the birth canal or from the immediate postnatal environment; or transient superficial contamination of the neonate that does not result in actual neonatal infection (7). In a report of universal SARS-CoV-2 nasopharyngeal RT-PCR screening, 2.2% (9/418) of neonates tested positive within 24 hours of birth; of those, eight had mothers with negative nasopharyngeal RT-PCR tests and no symptoms, and seven retested neonates were negative on the second test (31). This illustrates the difficulty in interpreting a single positive SARS-CoV-2 RT-PCR test in neonates. Persistence of a positive test on subsequent specimens is critical to differentiate whether there is superficial contamination (resulting in a false positive test) or actual neonatal infection. Viral isolation could similarly be falsely positive due to superficial contamination. The presence of additional positive tests of normally sterile specimen types (e.g. neonatal blood, lower respiratory tract samples, cerebrospinal fluid) can provide important information to enable differentiation of contamination from neonatal infection.
3. *Serologic testing:* Due to transplacental maternal antibody transfer during the second and third trimester, IgG found in the neonate is primarily reflective of maternal antibody and hence cannot be used to diagnose *in utero* infection. Maternal IgM and IgA do not cross the placenta unless there is placental disruption and are thought to represent the fetal immune response to infection. However, the sensitivity and specificity of IgM tests vary and usually are less reliable than molecular diagnostic tests based on nucleic acid amplification and detection (32). Both false negative IgM tests in infants with a variety of other congenital pathogens and false positive tests in healthy infants without infection have been reported (9, 10). Thus, a positive serological test always requires confirmatory testing of a second specimen, preferably using molecular diagnostic tests to directly detect the pathogen or otherwise a later serological test. SARS-CoV-2 IgM in the neonate between birth and less than 7 days after birth is assumed to represent fetal response to *in utero* infection whereas negative IgM at less than 7 days followed by detection of neonatal immune response after day 7 is assumed to reflect intrapartum or early postnatal infection (7).
4. *Mode of birth:* Sampling during a caesarean section, where both placenta and fetus may be delivered under sterile conditions, is less prone to contamination than through a vaginal birth, although there is still significant exposure to maternal blood during a caesarean section. For example, detection of virus by RT-PCR on the placental surface from a caesarean birth may be less likely to reflect potential contamination from maternal virus than a placenta that has been obtained via vaginal birth.

5. *Placental tissue and/or fetal tissue assays*: To definitively determine placental or fetal infection, placental or fetal tissue (as opposed to a surface swab, which can be contaminated) is needed (10). In a study comparing SARS-CoV-2 detection by in situ hybridization (ISH) or immunohistochemical (IHC) assay to the gold standard of tissue quantitative SARS-CoV-2 RT-PCR, the specificity of a positive test was far higher using ISH than IHC (100% vs 53.4%)(33). Additionally, identification of viral particles by electron microscopy may potentially yield false positive results (34). Hence, identification of SARS-CoV-2 in placental or fetal tissue with RT-PCR or ISH assays (with appropriate positive and negative controls) is viewed as more definitive than use of IHC, microscopy, or placental swab PCR testing.
6. *Placental tissue and amniotic fluid specimens for diagnosis*: While a placental tissue or amniotic fluid specimen positive for a pathogen is viewed as diagnostic of infection in the woman, it is not necessarily diagnostic of congenital infection in the neonate and requires confirmatory testing. While SARS-CoV-2 has been reported to be detected by RT-PCR in the placenta in several case reports, the presence of virus in the placenta has not always correlated with a positive RT-PCR test in the fetus/neonate (35, 36). Similarly, the finding of a pathogen in amniotic fluid alone does not necessarily correlate with fetal infection. While SARS-CoV-2 has been reported to be detected by RT-PCR in amniotic fluid in a small number of case reports, not all neonates had confirmed infection (37, 38). Thus, a positive SARS-CoV-2 assay on placenta or amniotic fluid alone is not viewed as confirmatory evidence of *in utero* infection.
7. *Umbilical cord blood*: Contamination of umbilical cord blood may occur due to cross-contamination with maternal blood during sample collection, maternal blood cells entering the fetal circulation through the placenta during pregnancy, or more frequently, maternal blood cells entering the fetal circulation during labour as a result of uterine contractions (39). Thus, a positive PCR in cord blood requires confirmation with either a fetal/neonatal peripheral blood sample or testing of another sterile or non-sterile sample.
8. *Viral detection in sterile vs non-sterile samples*: Viral detection in an otherwise sterile sample (e.g. neonatal blood, lower respiratory tract samples, cerebrospinal fluid) is preferred to samples from a more superficial, non-sterile sample (e.g. neonatal nasopharyngeal swab, saliva, stool) which is more likely to represent transient contamination.
9. *Timing of sample collection*: In general, definitive diagnosis of *in utero* infection requires a positive diagnostic test near the time of birth (see Annex 1) that is confirmed with a second positive specimen, while definitive diagnosis of intrapartum infection requires a negative diagnostic test near the time of birth, with a later test in the first few days after birth being positive and confirmed with a later second specimen.
10. *Persistence of the pathogen*: Persistence of a pathogen, documented through confirmatory testing of a second specimen collected within a few days (see Annex 1) of the first positive specimen, is important to be able to distinguish transient colonization, without infection, from true neonatal infection.
11. *Neonatal symptoms and signs*: SARS-CoV-2 infection in neonates may be asymptomatic; in a meta-analysis of 74 studies, 45% of 176 neonates with positive RT-PCR from a nasopharyngeal swab and/or the presence of specific IgM were asymptomatic (4). Clinical manifestation, such as neonatal respiratory distress, are not specific to SARS-CoV-2 infection, particularly in preterm infants (10). Therefore, neonatal symptoms and signs are not included in the classification system.

The proposed classification system to determine timing of vertical transmission of SARS-CoV-2 is thus based on three elements:

- 1) documented maternal infection, using the WHO COVID-19 case definitions (25), anytime during pregnancy for *in utero* infection; near the time of birth for intrapartum and early postnatal infection;
- 2) tests to evaluate the likelihood of early *in utero* or intrapartum exposure; and
- 3) tests to evaluate the later exposure/persistence of the virus or virus-specific immune response in the fetus/neonate.

The timing of vertical transmission (*in utero*, intrapartum and early postnatal) is classified in mutually exclusive categories, as follows:

- 1) confirmed;
- 2) possible (evidence is suggestive but not confirmatory for infection);
- 3) unlikely (little support for diagnosis but infection cannot be completely ruled out); and
- 4) indeterminate (when tests required to define classification have not been performed).

Detailed classification system tables for classification of *in utero* transmission in the case of a live birth; *in utero* transmission in the case of fetal demise; intrapartum; and early postnatal transmission are provided in Annex 1. Annex 2 provides an overall summary of time of sample collection, types of neonatal samples and test results required to categorize the timing of infection for neonates born alive to women with documented SARS-CoV-2 infection. Annex 3 summarizes the types of samples that are required to categorize *in utero* infection for fetal demise in women with documented SARS-CoV-2 infection.

Related WHO recommendations

A WHO scientific brief on breastfeeding and COVID-19, published on June 23 2020, concluded that data remain insufficient to conclude that SARS-CoV-2 can be transmitted postnatally from an infected mother to her infant through breast milk and that the benefits of breastfeeding, combined with adherence to infection prevention and control measures by breastfeeding mothers, outweigh the potential risk (11). WHO recommends that mothers with suspected or confirmed COVID-19 should be encouraged to initiate and continue breastfeeding (40).

Limitations/ Knowledge gaps

Defining vertical transmission of SARS-CoV-2 based on reports in the literature to date has been difficult. Most reports of vertical transmission have been based on a single positive neonatal RT-PCR in an upper respiratory tract specimen, with significant variation in the timing of sample collection. The mechanism by which potential *in utero* acquired fetal infection would result in neonatal naso-oro-pharyngeal positivity is unclear. The specificity of SARS-CoV-2 positive placental or amniotic fluid specimens alone to represent *in utero* infection is unclear, and the utility of SARS-CoV-2 IgM/IgA alone to diagnose neonatal infection is problematic given reports of positive IgM tests in asymptomatic neonates who have tested negative by nasopharyngeal RT-PCR. Thus, a combination of initial and confirmatory tests is required in the classification system to determine infection occurrence and timing.

Conclusions

At this time, there is limited evidence on the extent of SARS-CoV-2 vertical transmission and its timing, due to limitations related to the sensitivity and specificity of diagnostic testing, and lack of collection of appropriate specimens at appropriate times. This paucity of data is partly due to the lack of standardized definitions which would allow comparisons of data from different studies. The definitions proposed in this brief aim to increase our understanding of SARS-CoV-2 vertical transmission and its clinical consequences for the neonate. The classification system presented here may be updated in the future as new information becomes available.

References

1. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ*. 2020;370:m3320.

2. Schwartz DA, Dhaliwal A. Infections in Pregnancy With COVID-19 and Other Respiratory RNA Virus Diseases Are Rarely, If Ever, Transmitted to the Fetus: Experiences With Coronaviruses, Parainfluenza, Metapneumovirus Respiratory Syncytial Virus, and Influenza. *Arch Pathol Lab Med*;144(8):920-928, 2020.
3. Yap M, Debenham L, Kew T, Chatterjee SR, Allotey J, Stallings E, et al. Clinical manifestations, prevalence, risk factors, outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and postpartum: a living systematic review protocol. *BMJ Open*. 2020;10(12):e041868-e.
4. Raschetti R, Vivanti AJ, Vauloup-Fellous C, Loi B, Benachi A, De Luca D. Synthesis and systematic review of reported neonatal SARS-CoV-2 infections. *Nat Commun*. 2020;11(1):5164.
5. Woodworth KR, Olsen EO, Neelam V, Lewis EL, Galang RR, Oduyebo T, et al. Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy - SET-NET, 16 Jurisdictions, March 29-October 14, 2020. *MMWR Morb Mortal Wkly Rep*;69(44):1635-40, 2020.
6. Shah PS, Diambomba Y, Acharya G, Morris SK, Bitnun A. Classification system and case definition for SARS-CoV-2 infection in pregnant women, fetuses, and neonates. *Acta Obstet Gynecol Scand*. 2020;99(5):565-8.
7. Blumberg DA, Underwood MA, Hedriana HL, Lakshminrusimha S. Vertical Transmission of SARS-CoV-2: What is the Optimal Definition? *Am J Perinatol*. 2020;37(8):769-72.
8. Mahyuddin AP, Kanneganti A, Wong JLL, Dimri PS, Su LL, Biswas A, et al. Mechanisms and evidence of vertical transmission of infections in pregnancy including SARS-CoV-2s. *Prenat Diagn*. 2020;40:1655–70.
9. Voordouw B, Rockx B, Jaenisch T, Fraaij P, Mayaud P, Vossen A, et al. Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays. *Clin Microbiol Rev*. 2019;33(1): e00130-18.
10. Schwartz DA, Morotti D, Beigi B, Moshfegh F, Zafaranloo N, Patanè L. Confirming Vertical Fetal Infection With Coronavirus Disease 2019: Neonatal and Pathology Criteria for Early Onset and Transplacental Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From Infected Pregnant Mothers. *Arch Pathol Lab Med*. 2020;144(12):1451-6.
11. World Health Organization. Breastfeeding and COVID-19. Scientific brief, 23 June 2020. Geneva: World Health Organization; 2020.
12. World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions. Scientific Brief. 9 July 2020. Geneva: World Health Organization, 2020.
13. Andersson MI, Arancibia-Carcamo CV, Auckland K, Baillie JK, Barnes E, Beneke T, et al. SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus [version 2; peer review: 2 approved]. *Wellcome Open Res*. 2020;5:181.
14. Gengler C, Dubruc E, Favre G, Greub G, de Leval L, Baud D. SARS-CoV-2 ACE-receptor detection in the placenta throughout pregnancy. *Clin Microbiol Infect*. 2020(S1198-743X(20)30603-0).
15. Pique-Regi R, Romero R, Tarca AL, Luca F, Xu Y, Alazizi A, et al. Does the human placenta express the canonical cell entry mediators for SARS-CoV-2? *Elife*. 2020;9:e58716.
16. Sharps MC, Hayes DJL, Lee S, Zou Z, Brady CA, Almoghrabi Y, et al. A structured review of placental morphology and histopathological lesions associated with SARS-CoV-2 infection. *Placenta*. 2020;101:13-29.
17. Li M, Chen L, Zhang J, Xiong C, Li X. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study. *PLoS One*. 2020;15(4):e0230295.
18. Faure-Bardon V, Isnard P, Roux N, Leruez-Ville M, Molina T, Bessieres B, et al. Protein expression of angiotensin-converting enzyme 2, aSARS-CoV-2-specific receptor, in fetal and placental tissues throughout gestation: new insight for perinatal counseling. *Ultrasound Obstet Gynecol*. 2021;57:242–7.
19. van Doorn AS, Meijer B, Frampton CMA, Barclay ML, de Boer NKH. Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. *Aliment Pharmacol Ther*. 2020;52(8):1276-88.
20. Carosso A, Cosma S, Borella F, Marozio L, Coscia A, Ghisetti V, et al. Pre-labor anorectal swab for SARS-CoV-2 in COVID-19 pregnant patients: is it time to think about it? *Eur J Obstet Gynecol Reprod Biol*. 2020;249:98-9.

21. Hermes AC, Horve PF, Edelman A, Dietz L, Constant D, Fretz M, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Environmental Contamination and Childbirth. *Obstet Gynecol.* 2020;136(4):827-9.
22. Centeno-Tablante E, Medina-Rivera M, Finkelstein JL, Rayco-Solon P, Garcia-Casal MN, Rogers L, et al. Transmission of SARS-CoV-2 through breast milk and breastfeeding: a living systematic review. *Annals of the New York Academy of Sciences.* 2021;1484(1):32-54.
23. Demers-Mathieu V, Do DM, Mathijssen GB, Sela DA, Seppo A, Järvinen KM, et al. Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk. *J Perinatol.* 2020:1-10.
24. Shet A. Congenital and perinatal infections: throwing new light with an old TORCH. *Indian J Pediatr.* 2011;78(1):88-95.
25. World Health Organization. Public health surveillance for COVID-19 Interim guidance. 7 August 2020 Geneva: World Health Organization; 2020.
26. Wong TC, Lee ZY, Sia TLL, Chang AKW, Chua HH. Miscarriage Risk in COVID-19 Infection. *SN Compr Clin Med.* 2020:1-4.
27. Rana MS, Usman M, Alam MM, Khalid A, Ikram A, Salman M, et al. First trimester miscarriage in a pregnant woman infected with COVID-19 in Pakistan. *J Infect.* 2020;82:e27–e8.
28. Cosma S, Carosso AR, Cusato J, Borella F, Carosso M, Bovetti M, et al. Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. *Am J Obstet Gynecol.* 2020;S0002-9378(20):31177-7.
29. Rubio Lorente AM, Pola Guillén M, López Jimenez N, Moreno-Cid Garcia-Suelto M, Rodriguez Rodriguez E, Pascual Pedreño A. Study of amniotic fluid in pregnant women infected with SARS-CoV-2 in first and second trimester. Is there evidence of vertical transmission? *J Matern Fetal Neonatal Med.* 2020:1-3.
30. Yu N, Li W, Kang Q, Zeng W, Feng L, Wu J. No SARS-CoV-2 detected in amniotic fluid in mid-pregnancy. *Lancet Infect Dis.* 2020;20(12):1364.
31. McDevitt KEM, Ganjoo N, Mlangeni D, Pathak S. Outcome of universal screening of neonates for COVID-19 from asymptomatic mothers. *J Infect.* 2020;81(3):452-82.
32. Kimberlin DW, Stagno S. Can SARS-CoV-2 Infection Be Acquired In Utero?: More Definitive Evidence Is Needed. *JAMA.* 2020;323(18):1788-9.
33. Massoth LR, Desai N, Szabolcs A, Harris CK, Neyaz A, Crotty R, et al. Comparison of RNA In Situ Hybridization and Immunohistochemistry Techniques for the Detection and Localization of SARS-CoV-2 in Human Tissues. *Am J Surg Pathol.* 2021;45(1):14-24.
34. Kniss DA. Alternative interpretation to the findings reported in visualization of severe acute respiratory syndrome coronavirus 2 invading the human placenta using electron microscopy. *Am J Obstet Gynecol.* 2020;223(5):785-6.
35. Penfield CA, Brubaker SG, Limaye MA, Lighter J, Ratner AJ, Thomas KM, et al. Detection of severe acute respiratory syndrome coronavirus 2 in placental and fetal membrane samples. *Am J Obstet Gynecol MFM.* 2020;2(3):100133.
36. Baud D, Greub G, Favre G, Gengler C, Jatton K, Dubruc E, et al. Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection. *JAMA.* 2020;323(21):2198-200.
37. Zamaniyan M, Ebadi A, Aghajanpoor S, Rahmani Z, Haghshenas M, Azizi S. Preterm delivery, maternal death, and vertical transmission in a pregnant woman with COVID-19 infection. *Prenat Diagn.* 2020;40:1759–61.
38. Schwartz DA, Mohagheghi P, Beigi B, Zafaranloo N, Moshfegh F, Yazdani A. Spectrum of neonatal COVID-19 in Iran: 19 infants with SARS-CoV-2 perinatal infections with varying test results, clinical findings and outcomes. *J Matern Fetal Neonatal Med.* 2020 Aug 12:1-10.
39. Masuzaki H, Miura K, Miura S, Yoshiura K, Mapendano CK, Nakayama D, et al. Labor increases maternal DNA contamination in cord blood. *Clin Chem.* 2004;50(9):1709-11.
40. World Health Organization. COVID-19 Clinical management. Living guidance. 25 January 2021. Geneva: World Health Organization; 2021.

Acknowledgements

External Temporary Advisors: Denise Jamieson (Chair)(Emory University, USA), Quarraisha Abdool Karim (University of KwaZulu-Natal, South Africa), Jamila Al Abri (Ministry of Health, Oman), Maria Luiza Bazzo (Federal University of Santa Catarina, Brazil), Jose Guilherme Cecatti (University of Campinas, Brazil), Daniele De Luca (Paris Saclay University, France), Isabella Eckerle (University of Geneva, Switzerland), Stephanie Gaw (University of California, USA), Michelle Giles (Monash University, Australia), Cheryl Jones (The Sydney Children's Hospitals Network, Australia), David W Kimberlin (University of Alabama at Birmingham, USA), Tobias R. Kollmann (Telethon Kids Institute, Australia), Sunesh Kumar (All India Institute of Medical Sciences, India), Thanyawee Puthanakit (Chulalongkorn University, Thailand), Katayoun Tayeri (Tehran University of Medical Sciences, Iran). WHO COVID-19 LENS (Living Evidence Synthesis) working group: John Allotey (University of Birmingham, UK), Valeriane Leroy (Inserm 1027, Université Paul Sabatier Toulouse 3, France), Saurabh Mehta (Cornell University, USA), Emily Smith (The George Washington University, USA), Shakila Thangaratinam (University of Birmingham, UK), Mark Turner (University of Liverpool, UK). WHO Consultant for the development of the scientific brief: Lynne Mofenson (Elizabeth Glaser Pediatric AIDS Foundation, USA); Mercedes Bonet, Yasir Bin Nisar, Hector Pardo-Hernandez, Olufemi Oladapo, Anna Thorson (WHO Secretariat). This scientific brief was funded by WHO and UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored programme executed by WHO.

Annex 1. Categorization of the timing of mother-to-child transmission of SARS-CoV-2

In Utero SARS-CoV-2 Transmission - Live Birth: *In utero* SARS-CoV-2 transmission requires: **(#1)** evidence of maternal SARS-CoV-2 infection anytime during pregnancy **AND** **(#2)** *in utero* fetal SARS-CoV-2 exposure **AND** **(#3)** SARS-CoV-2 persistence or immune response in the neonate.

Category	(#1) Maternal infection: Suspect, probable or confirmed case of SARS-CoV-2 infection anytime during pregnancy, as defined by WHO COVID-19 case definitions (25).	(#2) Evidence <i>in utero</i> fetal exposure	(#3) Viral persistence/immune response
Confirmed		One or more of following samples at <i>age <24 hours</i> positive for SARS-CoV-2: <ul style="list-style-type: none"> • RT-PCR from sterile sample¹ • Placental tissue (RT-PCR or ISH) • RT-PCR from non-sterile sample² • Serology (IgM or IgA) 	One or more of following samples at <i>age 24-48 hours</i> positive for SARS-CoV-2: <ul style="list-style-type: none"> • RT-PCR from sterile sample¹
Possible		One or more of following samples at <i>age <24 hours</i> positive for SARS-CoV-2: <ul style="list-style-type: none"> • RT-PCR from sterile sample¹ • Placental tissue (RT-PCR, ISH, IHC or microscopy), placental swab RT-PCR • RT-PCR from non-sterile sample² • Serology (IgM or IgA) 	One or more of following samples at <i>age 24-48 hours</i> positive for SARS-CoV-2: <ul style="list-style-type: none"> • RT-PCR from non-sterile sample² OR <ul style="list-style-type: none"> • Positive serology (IgM or IgA) at <i>age 24 hours to <7 days</i>
Unlikely		One or more of following samples at <i>age <24 hours</i> positive for SARS-CoV-2: <ul style="list-style-type: none"> • RT-PCR sterile sample¹ • Placental tissue (RT-PCR, ISH, IHC or microscopy), placental swab RT-PCR • RT-PCR from non-sterile sample² • Serology (IgM or IgA) <hr/> All <i>in utero</i> fetal exposure tests (above) that were performed are negative for SARS-CoV-2	All tests that were performed on samples at <i>age 24-48 hours</i> are negative for SARS-CoV-2: <ul style="list-style-type: none"> • RT-PCR from sterile sample¹ • RT-PCR from non-sterile sample² OR <ul style="list-style-type: none"> • Negative serology (IgM or IgA) at <i>age 24 hours to <7 days</i> <hr/> One or more of following samples at <i>age 24-48 hours</i> positive for SARS-CoV-2: <ul style="list-style-type: none"> • RT-PCR from sterile sample¹ • RT-PCR from non-sterile sample² OR <ul style="list-style-type: none"> • Positive serology (IgM or IgA) at <i>age 24 hours to <7 days</i>
Indeterminate		One or more of following samples at <i>age <24 hours</i> positive for SARS-CoV-2 <ul style="list-style-type: none"> • RT-PCR from sterile sample¹ • Placental tissue (RT-PCR, ISH, IHC or microscopy), placental swab RT-PCR • RT-PCR from non-sterile sample² • Serology (IgM or IgA) <hr/> No <i>in utero</i> fetal exposure tests (above) performed	No viral persistence/immune response tests (above) performed <hr/> One or more of following samples at <i>age 24-48 hours</i> positive for SARS-CoV-2: <ul style="list-style-type: none"> • RT-PCR from sterile sample¹ • RT-PCR from non-sterile sample² OR <ul style="list-style-type: none"> • Positive serology (IgM or IgA) at <i>age 24 hours to <7 days</i>

IHC: immunohistochemistry; ISH: in-situ hybridization; RT-PCR= reverse transcription polymerase chain reaction.

¹ Sterile sample: amniotic fluid (sterile collection caesarean section prior to rupture of membranes or amniocentesis), neonatal blood (cord blood needs confirmation with peripheral blood or other sample), lower respiratory tract samples obtained by bronchoscopic or non-bronchoscopic bronchoalveolar lavage, bronchial or tracheal aspirate, or cerebrospinal fluid; ² Non-sterile sample: upper respiratory tract samples (e.g. naso- or oropharyngeal swab or aspirate) or other non-sterile samples (e.g. stool).

In Utero SARS-CoV-2 Transmission - Fetal Demise: *In utero* SARS-CoV-2 infection in the case of fetal demise requires: **(#1)** evidence of maternal SARS-CoV-2 infection anytime during pregnancy **AND (#2)** detection of SARS-CoV-2 in fetal tissue, amniotic fluid, or placental specimens.

	(#1) Maternal infection: Suspect, probable or confirmed case of SARS-CoV-2 infection anytime during pregnancy, as defined by WHO COVID-19 case definitions (25).
Category	(#2) Detection of SARS-CoV-2
Confirmed	Fetal tissue ¹ positive for SARS CoV-2 on RT-PCR or ISH
Possible	<ul style="list-style-type: none"> Fetal tissue¹ for SARS-CoV-2 not tested <p>AND</p> <p>One or more of the following is positive for SARS-CoV-2:</p> <ul style="list-style-type: none"> Fetal tissue¹ IHC or microscopy or fetal swab RT-PCR Amniotic fluid² Placental tissue (RT-PCR, ISH, IHC or microscopy) or placental swab RT-PCR
	<ul style="list-style-type: none"> Fetal tissue¹ for SARS-CoV-2 negative by RT-PCR or ISH <p>AND</p> <ul style="list-style-type: none"> Amniotic fluid² positive for SARS-CoV-2
Unlikely	<ul style="list-style-type: none"> Fetal tissue¹ negative for SARS-CoV-2 by RT-PCR or ISH <p>AND</p> <p>One or more of following is positive for SARS-CoV-2:</p> <ul style="list-style-type: none"> Fetal tissue¹ IHC or microscopy or fetal swab RT-PCR Placental tissue (RT-PCR, ISH, IHC or microscopy) or placental swab RT-PCR

IHC= immunohistochemistry; ISH=in situ hybridization; RT-PCR= reverse transcription polymerase chain reaction.

¹ Fetal tissue from sterile site, such as fetal organ (e.g. lung, liver, brain); testing of multiple specimens recommended; ² Amniotic fluid from sterile collection prior to rupture of membranes.

Intrapartum SARS-CoV-2 Transmission: Intrapartum SARS-CoV-2 transmission requires: **(#1)** evidence of maternal SARS-CoV-2 infection near the time of birth¹ **AND (#2)** evidence of lack of *in utero* fetal SARS-CoV-2 exposure **AND (#3)** SARS-CoV-2 intrapartum exposure with viral persistence or immune response in the infant.

Category	(#2) Lack of <i>in utero</i> fetal exposure	(#3) Intrapartum exposure with viral persistence/ immune response
Confirmed	<p>At least one test obtained at <i>age <24 hours</i> was performed and negative for SARS-CoV-2 (all tests performed must be negative; otherwise classify as <i>in utero</i> exposure, above)</p> <ul style="list-style-type: none"> • RT-PCR from sterile sample² • Placental tissue (RT-PCR, ISH, IHC or microscopy), placental swab RT-PCR • RT-PCR from non-sterile sample³ • Negative serology (IgM or IgA) 	<p>One or more of following samples at <i>age 24-48 hours</i> positive for SARS-CoV-2:</p> <ul style="list-style-type: none"> • RT-PCR from sterile sample² • RT-PCR from <i>non-sterile</i> sample³ that is corroborated by a positive PCR on a second non-sterile sample at age >48 hours to 7 days <p>OR</p> <ul style="list-style-type: none"> • Positive serology (IgM or IgA) at <i>age 7-14 days</i> that is corroborated by a positive serology test on a second sample obtained within 10 days of the first positive test⁴
Possible	<ul style="list-style-type: none"> • No <i>in utero</i> fetal exposure tests (above) performed 	<p>One or more of following samples at <i>age 24-48 hours</i> positive for SARS-CoV-2:</p> <ul style="list-style-type: none"> • RT-PCR from sterile sample² • RT-PCR from <i>non-sterile</i> sample³ that is corroborated by a positive RT-PCR on a second non-sterile sample at age >48 hours to 7 days <p>OR</p> <ul style="list-style-type: none"> • Positive serology (IgM or IgA) at <i>age 7-14 days</i> that is corroborated by a positive serology test on a second sample obtained within 10 days of the first positive test⁴
Unlikely	<ul style="list-style-type: none"> • No <i>in utero</i> fetal exposure tests performed 	<p>One or more of following samples at <i>age 24-48 hours</i> positive for SARS-CoV-2:</p> <ul style="list-style-type: none"> • RT-PCR from sterile sample² with a negative RT-PCR on second sample at age >48 hours to 7 days • RT-PCR from non-sterile sample³ with a negative RT-PCR on second non-sterile sample at age >48 hours to 7 days <p>OR</p> <ul style="list-style-type: none"> • Positive serology (IgM or IgA) at <i>age 7-14 days</i> with negative serology test on a second sample obtained within 10 days of the first positive test⁴

IHC: immunohistochemistry; ISH: in-situ hybridization; RT-PCR= reverse transcription polymerase chain reaction.

¹ “Near the time of birth”: Available data suggest replication competent SARS-CoV-2 virus is not detectable after 8-10 days of illness. Thus, for transmission during the intrapartum period to the infant, SARS-CoV-2 diagnosis would need to have occurred in the woman from 14 days prior to 2 days after birth; ² Sterile sample: amniotic fluid (sterile collection caesarean section prior to rupture of membranes or amniocentesis), neonatal blood (cord blood needs confirmation with peripheral blood or other sample), lower respiratory tract samples obtained by bronchoscopic or non-bronchoscopic bronchoalveolar lavage, bronchial or tracheal aspirate, or cerebrospinal fluid; ³ Non-sterile sample: upper respiratory tract samples (e.g. nasopharyngeal or oropharyngeal swab or aspirate) or other non-sterile samples (e.g. stool); ⁴ Second serology sample must be IgM to corroborate initial positive IgM, or IgA to corroborate initial positive IgA.

Early Postnatal SARS-CoV-2 Transmission (age >48 hours-28 days): Postnatal SARS-CoV-2 transmission requires: **(#1)** evidence of maternal infection near the time of birth¹ **AND (#2)** evidence to show lack of *in utero* and lack of intrapartum exposure **AND (#3)** SARS-CoV-2 early postnatal exposure and viral persistence or immune response in the infant.

Category	(#2) Lack of <i>in utero</i>/intrapartum exposure	(#3) Early postnatal exposure with viral persistence/immune response
Confirmed	<p>At least one test obtained at <i>age <48 hours</i> was performed and negative for SARS-CoV-2 (all tests performed at <i>age <48 hours</i> must be negative)</p> <ul style="list-style-type: none"> • RT-PCR from sterile sample² • Placental tissue (RT-PCR, ISH, IHC or microscopy), placental swab RT-PCR • RT-PCR from non-sterile sample³ • Negative serology (IgM or IgA) at <i>age <14 days</i> 	<p>One or more of following samples at <i>age ≥48 hours</i> positive for SARS-CoV-2:</p> <ul style="list-style-type: none"> • RT-PCR from sterile sample² • RT-PCR from non-sterile sample³ that is corroborated by a positive PCR on a second non-sterile sample obtained within 10 days of first positive test obtained at <i>≥48 hours</i> <p>OR</p> <ul style="list-style-type: none"> • Positive serology (IgM or IgA) at <i>age >14 days</i> that is corroborated by a second positive serology test obtained within 10 days of the first positive test at <i>age >14 days</i>⁴
Possible	<ul style="list-style-type: none"> • <u>No <i>in utero</i> fetal/intrapartum exposure tests performed</u> 	<p>One or more of following samples at <i>age ≥48 hours</i> positive for SARS-CoV-2:</p> <ul style="list-style-type: none"> • RT-PCR from sterile sample² • RT-PCR from non-sterile sample³ that is corroborated by a positive PCR on a second non-sterile sample obtained within 10 days of first positive test <p>OR</p> <ul style="list-style-type: none"> • Positive serology (IgM or IgA) at <i>age >14 days</i> that is corroborated by a second positive serology test obtained within 10 days of the first positive test⁴
Unlikely	<p><u>No <i>in utero</i> fetal/intrapartum exposure tests performed</u></p>	<p>One or more of following samples at <i>age ≥48 hours</i> positive for SARS-CoV-2:</p> <ul style="list-style-type: none"> • RT-PCR from non-sterile sample³ with negative RT-PCR on a second non-sterile sample obtained within 10 days of first positive test <p>OR</p> <ul style="list-style-type: none"> • Positive serology (IgM or IgA) at <i>age >14 days</i> with negative serology test on second serology test obtained within 10 days of the first positive test⁴
Indeterminate	<ul style="list-style-type: none"> • <u>No <i>in utero</i> fetal/intrapartum exposure tests performed</u> 	<p>One or more of following samples at <i>age ≥48 hours</i> positive for SARS-CoV-2:</p> <ul style="list-style-type: none"> • RT-PCR from non-sterile sample³ <u>without</u> a second corroboratory test <p>OR</p> <ul style="list-style-type: none"> • Positive serology (IgM or IgA) at <i>age >14 days</i> <u>without</u> a second corroboratory test⁴

Note: It is difficult to distinguish source of postnatal infection, and this definition does not attempt to identify source (e.g. breast milk, infected mother, environment). IHC: immunohistochemistry; ISH: in-situ hybridization; RT-PCR= reverse transcription polymerase chain reaction.

¹ “Near the time of birth”: Available data suggest replication competent SARS-CoV-2 virus is not detectable after 8-10 days of illness. Thus, for transmission during the intrapartum/peripartum period to the infant, SARS-CoV-2 would need to have occurred in the woman from 14 days prior to 2 days after birth; ² Sterile sample: amniotic fluid (sterile collection caesarean section prior to rupture of membranes or amniocentesis); neonatal blood (cord blood needs confirmation with peripheral blood or other sample), cerebrospinal fluid, or lower respiratory tract samples obtained by bronchoscopic or non-bronchoscopic bronchoalveolar lavage, broncho- or tracheal aspirate; ³ Non-sterile sample: upper respiratory tract samples (e.g. nasopharyngeal or oropharyngeal swab or aspirate) or other non-sterile samples (e.g. stool); ⁴ Second serology sample must be IgM to confirm initial positive IgM, or IgA to confirm initial positive IgA.

Annex 2. Summary of time of sample collection, type of samples and test for categorization of timing of vertical transmission for live-born infants of women with documented SARS-CoV-2 infection

		Early <i>in utero</i> exposure testing						Later exposure testing											
Time of sample collection		Birth to age <24 hours								24-48 hr	≥48 hr	24-48 hr	≥48 hr	Repeated within 10 d	24 hr-7 d	7-14 d	Repeated within 10 d	>14 d	Repeated within 10 d
Type of sample and test	Sterile sample			Non-sterile sample			Serology (IgM/IgA)	Sterile ⁴ sample		Non-sterile ⁵ sample			Serology (IgM/IgA)						
	Neonatal blood	Amniotic fluid	Lower respiratory tract ¹ /CSF	Placenta RT-PCR/ISH	Placenta IHC/microscopy	Upper respiratory tract ² /other ³													
Timing of transmission and categories	In Utero (live birth) (maternal infection anytime during pregnancy)																		
	Confirmed	+	+	+	+		+	+	+										
	Possible	+	+	+	+	+	+	+	+		+			+					
	Unlikely	+	+	+	+	+	+	+	NEG		NEG			NEG					
		NEG	NEG	NEG	NEG	NEG	NEG	NEG											
	Indeterminate	+	+	+	+	+	+	+	ND		ND			ND					
		ND	ND	ND	ND	ND	ND	ND			+			+					
	Intrapartum (maternal infection near the time of birth)																		
	Confirmed	NEG	NEG	NEG	NEG	NEG	NEG	NEG	+		+	+ to 7 d			+	+			
	Possible	ND	ND	ND	ND	ND	ND	ND	+		+	+ to 7 d			+	+			
	Unlikely	ND	ND	ND	ND	ND	ND	ND	+	NEG	+	NEG			+	NEG			
	Early Postnatal (maternal infection near the time of birth)																		
	Confirmed	NEG	NEG	NEG	NEG	NEG	NEG	NEG	NEG	+	NEG	+	+	NEG	NEG			+	+
	Possible	ND	ND	ND	ND	ND	ND	ND	ND	+	ND	+	+	ND	ND			+	+
	Unlikely	ND	ND	ND	ND	ND	ND	ND	ND		ND	+	NEG	ND	ND			+	NEG
	Indeterminate	ND	ND	ND	ND	ND	ND	ND	ND		ND	+	ND	ND	ND			+	ND

CSF: cerebrospinal fluid; d: age in days; hr: age in hours; ISH: in situ hybridization; IHC: immunohistochemistry; ND: not done; RT-PCR: reverse transcription polymerase chain reaction; ¹ Lower respiratory tract: bronchoscopic or non-bronchoscopic bronchoalveolar lavage, broncho- or tracheal aspirate; ² Upper respiratory tract: nasopharyngeal or oropharyngeal swab or aspirate; ³ Other non-sterile site (e.g. stool); ⁴ Sterile sample: neonatal blood, cerebrospinal fluid, lower respiratory tract; ⁵ Non-sterile sample: upper respiratory tract or other non-sterile site; + = positive test (meets category if one or more tests positive for early exposure plus one or more tests positive for later exposure). NEG = negative test (meets category if all tests that were performed are negative, early or later exposure). Colour code: **In utero - Blue -**: dark blue: positive test, light blue: negative test; **Intrapartum - Orange**: dark orange positive test, light orange negative test; **Postnatal - Red**: dark red positive test, light red negative test; **Gray**: not done.

Annex 3. Summary of type of samples and test for categorization of vertical transmission for fetal demise in women with documented SARS-CoV-2 infection

Category	Type of sample and test			
	Fetal tissue ¹ RT-PCR or ISH	Fetal tissue IHC or microscopy or fetal swab RT- PCR	Amniotic fluid (sterile)	Placental tissue (RT-PCR, ISH, IHC or microscopy) or placental swab RT-PCR
Confirmed	+	+	+	+
	+	NEG or ND	+	+
	+	+	+	NEG or ND
	+	+	NEG or ND	+
	+	+	NEG or ND	NEG or ND
	+	NEG or ND	+	NEG or ND
	+	NEG or ND	NEG or ND	+
	+	NEG or ND	NEG or ND	NEG or ND
Possible	ND	+	+	+
	ND	NEG or ND	+	+
	ND	+	NEG or ND	+
	ND	+	+	NEG or ND
	ND	+	NEG or ND	NEG or ND
	ND	NEG or ND	+	NEG or ND
	ND	NEG or ND	NEG or ND	+
	NEG	NEG or ND	+	NEG or ND
Unlikely	NEG	+	NEG or ND	+
	NEG	+	NEG or ND	NEG or ND
	NEG	NEG or ND	NEG or ND	+

CS: caesarean section; IHC: immunohistochemistry; ISH: in situ hybridization; ND = not done; RT-PCR: reverse transcription polymerase chain reaction; ROM: rupture of membranes; + = positive test (meets category if one or more tests positive); NEG = negative test (meets category if all tests that were performed are negative); ¹Fetal tissues from sterile site such as fetal organ (e.g. lung, live, brain), testing of multiple specimens recommended; ² Amniotic fluid from sterile collection prior to rupture of membranes.

WHO continues to monitor the situation closely for any changes that may affect this scientific brief. Should any factors change, WHO will issue a further update. Otherwise, this scientific brief will expire 2 years after the date of publication.